MaxCyte (MXCT) versus Its Peers Head-To-Head Review

MaxCyte (NASDAQ:MXCT) is one of 109 publicly-traded companies in the “Life Sciences Tools & Services” industry, but how does it contrast to its rivals? We will compare MaxCyte to related companies based on the strength of its valuation, analyst recommendations, institutional ownership, dividends, profitability, risk and earnings.

Volatility and Risk

MaxCyte has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, MaxCyte’s rivals have a beta of 1.14, suggesting that their average stock price is 14% more volatile than the S&P 500.

Profitability

This table compares MaxCyte and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MaxCyte	-114.77%	-18.92%	-16.14%
MaxCyte Competitors	-540.73%	-166.48%	-13.59%

Valuation and Earnings

This table compares MaxCyte and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MaxCyte	$31.05 million	-$44.63 million	-4.39
MaxCyte Competitors	$2.24 billion	$55.11 billion	-13.39

MaxCyte’s rivals have higher revenue and earnings than MaxCyte. MaxCyte is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

68.8% of MaxCyte shares are held by institutional investors. Comparatively, 54.9% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 4.1% of MaxCyte shares are held by company insiders. Comparatively, 15.0% of shares of all “Life Sciences Tools & Services” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and price targets for MaxCyte and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1	1	1	0	2.00
MaxCyte Competitors	947	3159	5473	176	2.50

MaxCyte presently has a consensus target price of $5.00, indicating a potential upside of 244.83%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 1.85%. Given MaxCyte’s higher possible upside, analysts plainly believe MaxCyte is more favorable than its rivals.

Summary

MaxCyte rivals beat MaxCyte on 7 of the 13 factors compared.

About MaxCyte

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.